Prognostic implications of the arginine metabolism in patients at nutritional risk: A secondary analysis of the randomized EFFORT trial

Abstract

BackgroundArginine, a conditionally essential amino acid, is key component in metabolic pathways including immune regulation and protein synthesis. Depletion of arginine contributes to worse outcomes in severely ill and surgical patient populations. We assessed prognostic implications of arginine levels and its metabolites and ratios in polymorbid medical inpatients at nutritional risk regarding clinical outcomes and treatment response. MethodsWithin this secondary analysis of the randomized controlled Effect of early nutritionalsupporton Frailty, Functional Outcomes, and Recovery of malnourished medical inpatients Trial (EFFORT), we investigated the association of arginine, its metabolites and ratios (i.e., ADMA and SDMA, ratios of arginine/ADMA, arginine/ornithine, and global arginine bioavailability ratio) measured on hospital admission with short-term and long-term mortality by means of regression analysis. ResultsAmong the 231 patients with available measurements, low arginine levels ≤90.05 μmol/l (n=86; 37%) were associated with higher all-cause mortality at 30 days (primary endpoint, adjusted HR 3.27, 95% CI 1.86 to 5.75, p<0.001) and at 5 years (adjusted HR 1.50, 95% CI 1.07 to 2.12, p=0.020). Arginine metabolites and ratios were also associated with adverse outcome, but had lower prognostic value. There was, however, no evidence that treatment response was influenced by admission arginine levels. ConclusionThis secondary analysis focusing on medical inpatients at nutritional risk confirms a strong association of low plasma arginine levels and worse clinical courses. The potential effects of arginine-enriched nutritional supplements should be investigated in this population of patients. Clinical Trial Registrationclinicaltrials.gov as NCT02517476 (registered 7 August 2015)